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Abstract 
Background: Gold standard for the diagnosis of oral dysplasia (OD) oral squamous cell carcinoma (OSCC) and 
malignant lesions is the histological examination. 
Several adjunctive diagnostic techniques have been proposed in order to increase the sensitivity (SE) and specifi-
city (SP) of conventional oral examination and to improve the diagnostic first level accuracy.
The aim of this study is to perform a systematic review on non-invasive tools for diagnosis of OD and early 
OSCC.
Material and Methods: Medline, Scopus, Web of Knowledge databases were searched, using as entry terms “oral 
dysplasia AND diagnosis” / ”oral cancer AND diagnosis”. Data extracted from each study included number of 
lesions evaluated, histopathological diagnosis, SE, SP, positive and negative predictive values (PPV and NPV), 
diagnostic accuracy (DA) and the main conclusions.
Results: After title and abstract scanning of 11.080 records, we selected 35 articles for full text evaluation. Most 
evaluated tools were autofluorescence (AF), chemiluminescence (CL), toluidine blu (TL) and chemiluminescence 
associated with toluidine blue (CLTB). 
Conclusions: There is a great inhomogeneity of the reported values and there is no significant evidence of supe-
riority of one tool over the other. Further clinical trials with a higher level of evidence are necessary in order to 
assess the real usefulness visual diagnostic tools.
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Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most 
common malignant tumour, with an incidence of more 
than 500.000 cases per year (1). 
The most important prognostic factor influencing the 
disease-specific survival rate is the tumour stage at 
diagnosis. Patients with stage I tumours have a 5-year 
survival rate of 75%, which dramatically decreases in 
patients with tumours in stage III or IV, being 49% and 
30%, respectively (1,2).
The diagnostic pathway for oral suspicious lesions usu-
ally starts with the conventional objective examination 
(COE) based on inspection and palpation of the oral mu-
cosa with the support of an incandescent light available 
on the dental chair. It is well known that COE mainly 
depends on a subjective interpretation, which is a conse-
quence of the experience of the operator. Moreover, oral 
epithelial dysplasia (OED) and early OSCC may already 
be present within areas of oral mucosa macroscopically 
normal, as well as within the context of oral potentially 
malignant disorders such as leukoplakia, erythroplakia, 
submucous fibrosis and oral lichen planus (3).
The gold standard for the diagnosis of oral dysplastic 
and neoplastic malignant lesions is the histological ex-
amination (4). Incisional or excisional biopsy techniques 
are the most reliable methods to collect a surgical speci-
men suitable for microscopic evaluation. However, de-
spite the little invasivity of such techniques, they still 
have some disadvantages in terms of morbidity and pos-
sible artifacts induced by the method of collection. 
In a recent paper, Mehrotra et al. indicated that there are 
two approaches for detection of oral dysplasia and cancer: 
1) oral cancer screening programs that identify asympto-
matic patients with suspicious lesions and 2) specific di-
agnostic tools to identify dysplasia and early oral cancers 
in asymptomatic patients with an oral abnormality (5).
Several visual diagnostic aids have been developed as 
adjunctive tools in order to increase the diagnostic ac-
curacy (DA) and enhance the specificity (SP) and sen-
sitivity (SE) of the conventional diagnostic pathway. 
However, results of studies on the usefulness of such 
tools show impressive discrepancies with regard to val-
ues such as the positive or negative predictive values 
(PPV, NPV), when the same tools is evaluated by dif-
ferent researchers.
The aim of this study is to perform a systematic review 
on non-invasive tools for the diagnosis of OED and 
OSCC, taking into account factors as SE, SP, PPV, NPV 
and DA.
Material and Methods
The databases Medline, Scopus and Web of Knowledge 
were searched, using as entry terms “oral dysplasia 
AND diagnosis” / ”oral cancer AND diagnosis”. No 
time limits were specified in the present research. 
Search flow is shown in figure 1. Papers with abstract 
unavailable were excluded for further evaluation. 
Titles and abstract were screened and the following ex-
clusion criteria were applied:
- papers not in English.
- studies ex vivo or based on animal models.
- typology of the study: case reports, case series with 
less than 10 patients, conference proceedings, personal 
communications, editorials, descriptive studies and re-
views.
- studies that analyse COE, invasive diagnostic tools 
(e.g. scalpel biopsy) or minimally invasive diagnostic 
tools (e.g. brush biopsy, exfoliative cytology) alone. 
- studies that analyse salivary biomarkers.
- studies including also tumours of other head and neck 
regions (e.g. oropharynx).
Papers with equivocal abstracts were included for full-
text evaluation. Further studies were excluded after 
full-text reading, if not pertinent with aim of the present 
review.
Data extracted from each study included authors and 
publication year, typology of the study, diagnostic tool 
analysed, number of lesions evaluated, (if present) his-
topathological diagnosis, (if present) SE, SP, PPV, NPV, 
DA and the main conclusions of the study (Tables 1 and 
1 continue,2).
SE and SP measure the accuracy of a test without any 
relation to the disease or population, whereas PPV and 
NPV measure the proportion of people whose test results 
reflect their health status. DA is the proportion of true 
positive results (both true positive and true negative) in a 
selected population, with regard to a specific disease.
The mean value of each variable analysed was calcu-
lated; range and standard deviation (SD) were indicated 
for samples having > 2 values. 
Level of evidence of each study was assessed according 
to the Oxford Evidence-based Medicine (OEBM) Lev-
els for Diagnosis updated in March 2009.
Results
Twenty-three papers were eventually selected for the 
present systematic review when using “oral dysplasia 
AND diagnosis” as entry terms. The use of “oral cancer 
AND diagnosis” as entry terms allowed the identifica-
tion of further 25 full-text manuscripts (6-39).
Twenty-three studies were perspective (OEBM level: 2b), 
4 studies were pilot (OEBM level: 3b), 3 studies were 
case-control (OEBM level: 4), 4 studies were cross-sec-
tional (OEBM level: 2b). Only one study was a perspec-
tive randomized clinical trial (RCT) (OEBM level: 1b).
Eight typologies of non-invasive visual diagnostic tools 
were identified (Table 3).
Mean SE and SP (with SD) are shown in figures 2,3.
1. Auto fluorescence (AF) - Direct visual fluorescence 
examination (DVFE) 
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Among 12 studies evaluating AF/DVFE, 8 were per-
spective (OEBM level: 2b), 2 were cross-sectional 
(OEBM level: 2b), 1 was a pilot study (OEBM level: 
3b) and 1 was a perspective RCT (OEBM level: 1b) 
(6,10,13,14,16-18,24,29,32,33,35).
Data on SE were reported in 10 studies, while informa-
tion on SP was available in 11 studies. Mean SE was 
72.4% ranging from 20% to 100% (SD = 27.1). Mean SP 
was 63.79% ranging from 15.3% to 100% (SD = 28.17). 
Data on PPV were available in 5 studies (mean: 55.74%, 
ranging from 15.1% to 92%, SD = 36.71); data on NPV 
were available in 5 studies (mean: 79.76%, ranging from 
61% to 100%, SD = 15.99); DA was reported in 1 study 
(55%).  
2. Chemiluminescence (CL)
Among 5 studies evaluating CL, 4 were perspective 
(OEBM level: 2b) and 1 was observational cross-sec-
tional (OEBM level: 2b) (7,15,38).
Data on SE and SP were reported in 4 studies. Mean SE 
was 86.72%, ranging from 69.6% to 100% (SD = 15.65). 
 
Fig. 1. Flow-chart diagram for the selection of the 35 studies included in the present analysis.
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Mean SP was 38.37%, ranging from 14.2% to 81.5% 
(SD = 29.59). 
Data on PPV and NPV were available in 2 studies (mean 
PPV: 74.5%; mean NPV: 63%); DA was reported in 1 
study (80.6%). 
3. Toluidine Blue (TB)
Among 9 studies evaluating TB, 7 were perspective 
(OEBM level: 2b) and 2 were cross-sectional (1 perspec-
tive cross-sectional and 1 observational cross-sectional) 
(OEBM level: 2b) (6,8,11,26,28,34,38,39).
Data on SE and SP were available in 8 studies. Mean 
SE resulted 72.5%, ranging from 56.1% to 95% (SD = 
13.13). Mean SP resulted 61.4%, ranging from 25% to 
74.1% (SD=15.95). 
Data on PPV were available in 5 studies (mean: 58.16%, 
ranging from 35.2% to 84.6%, SD=19.4); data on NPV 
were available in 5 studies (mean: 95.3%, ranging from 
66.7% to 90.9%, SD=11.42); data on DA were available 
in 2 studies (mean: 75.49%).
A perspective study evaluating Methylene Blue (MB) 
was also identified. In this study SE (90%), SP (69%), 
PPV (74%) and NPV (84%) were available (37).
4. Chemiluminescence associated with Toluidine Blue 
(CLTB)
Among 4 studies evaluating CLTB, 3 were perspective 
(OEBM level: 2b) and 1 was cross-sectional (OEBM 
level: 2b) (7,12,22,35).
Data on SE were available in 3 studies, while data on 
SP were available in 4 studies. Mean SE was 53.93%, 
ranging from 0% to 81.8% (SD = 46.72). Mean SP was 
66.44%, ranging from 37.5% to 97.5% (SD=25.88). 
Data on PPV were available in 2 studies (mean: 87.2%); 
data on NPV was available in 3 studies (mean: 76.1%, 
ranging from 33.3% to 100%). DA was not reported in 
any study.
5. Bengal Rose (BR)
The 2 studies evaluating BR were pilot studies (OEBM 
level: 3b) (9,23).
 
Diagnostic tool Number of studies References 
Direct visual fluorescence examination (DVFE) – Autofluorescence (AF) 12 (6, 10, 13, 14, 16-18, 24, 29, 32, 33, 35) 
Chemiluminescence (CL) 5 (7, 15, 36, 38) 
Toluidine Blue (TB) 9 (6, 8, 11, 26, 28, 34, 38, 39) 
Chemiluminescence associated with Toluidine Blue (CLTB) 4 (7, 12, 22, 35) 
Bengal Rose (BR) 2 (9, 23) 
Laser-induced fluorescence examination (LIFE) 2 (19, 21) 
5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) fluorescence 1 (27) 
Optical spectroscopy (including fluorescence spectroscopy-FS, depth-sensitive optical 
spectroscopy-DSOS, elastic scattering spectroscopy-ESS and Raman spectroscopy-RS) 4 (20, 25, 30, 31) 
Table 3. Typology of not invasive visual diagnostic tools identified in this review and number of related studies.
 
Fig. 2. Sensitivity with relative standard deviation of non-invasive visual diagnostic tools analysed. DVFE: Direct visual fluo-
rescence examination. VL: ViziLite®. TB: Toluidine Blue. VLP: ViziLite Plus®. RB: Bengal Rose. LIFE: Laser-induced fluo-
rescence examination. 5-ALA PPIX: 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) fluorescence.
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Data on SE were available in both the papers (mean: 
91.95%); mean SP was available in 1 study (73.7%). 
Data on PPV and NPV were not available in any study, 
while DA was reported in 1 study (DA: 90%).
6. Laser-induced fluorescence examination (LIFE)
Among the 2 studies evaluating LIFE, 1 was perspec-
tive and 1 was a case-control study (OEBM level: 2b 
and 4, respectively) (19,21). 
Data on SE and SP were available in 1 study. SE ranged 
from 100% to 95% and SP ranged from 96% to 86% 
taking into account the histopathological diagnosis.
Data on PPV, NPV and DA were not reported in any 
study.
7. 5-aminolevulinic acid (ALA) induced protoporphy-
rin IX (PPIX) fluorescence
Only one perspective study evaluating this tool was in-
cluded in the present research (OEBM level: 2b) (27).
SE was 99%; SP was 60%. Data on PPV, NPV and DA 
were not available.
8. Optical spectroscopy
One case-control study regarding fluorescence spectros-
copy (FS), one pilot study regarding Raman spectroscopy 
(RS), one perspective study regarding Elastic scattering 
spectroscopy (ESS) and one case-control study regard-
ing an experimental assessment of depth-sensitive opti-
cal spectroscopy (DSOS) were identified (OEBM level: 
4, 3b, 2b and 4, respectively) (20,25,30,31).
Among these, SE and SP were available for FS (SE: 
93.8%, SP: 88.5%), RS (SE: 100%, SP: 77%) and ESS 
(SE: 72%, SP: 75%) (25,30,31).
Data on PPV, NPV and DA were not available in any 
study.
Discussion
The principles of functioning of non-invasive visual di-
agnostic tools for OSCC and dysplastic lesions are very 
different, being based on diverse specific cellular and 
tissue characteristics. Such a great diversity may partly 
explain the impressive discrepancy of results obtained 
in the studies analysed. Another reason which can give 
some reasons for the wide range of results, in terms of 
SE, SP and DA is the great variability both of the typol-
ogy of the studied lesions and of the diagnostic criteria 
used for the clinical and histological assessment of such 
lesions. The difficulty to establish univocal and broad-
ly-accepted criteria for the assessment of the OED has 
been widely reported, particularly, with regard to the in-
ter- and intra-observer disagreement for the diagnosis.
Moreover, SE and SP may well depend on the degree of 
development of a lesion, seeming quite reasonable that 
both these indicators increase with the progression of a 
lesion from normal, to dysplastic, early neoplastic and 
invasive and destructive lesion.
Taking into account the abovementioned considerations, 
we report a short discussion for each tool analysed:
- Auto fluorescence (AF) - Direct visual fluorescence 
examination (DVFE)
Auto fluorescence (AF) uses natural fluochromes which 
are located within the epithelium and the submucosa 
and which are excited when irradiated with specific 
wavelengths. Using wavelengths between 375 and 
440 nm, some fluochromes show fluorescence in the 
range of the green colour. Following such irradiation, 
normal, unaltered mucosa emits a pale green AF light 
when viewed through a selective, narrow-band filter. A 
 
Fig. 3. Specificity with relative standard deviation of non-invasive visual diagnostic tools analysed. DVFE: Direct visual fluo-
rescence examination. VL:ViziLite®. TB: Toluidine Blue. VLP: ViziLite Plus®. RB: Bengal Rose. LIFE: Laser-induced fluores-
cence examination. 5-ALA PPIX: 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) fluorescence.
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proper filtration is crucial, due to the intense light used 
for excitation of the fluorochromes (13,15). Areas of 
reduced AF (dark areas) are suspicious for epithelial 
dysplasia or OSCC, whereas normal mucosa appears 
bright green (10).
The VELscopeTM (LED Medical Diagnostics Inc., 
Barnaby, Canada) system consists of a non-invasive de-
vice designed to visualise early mucosal changes using 
the principles of tissue AF. According to such principles, 
dysplastic changes should be associated with a loss of 
stromal AF (29,32). It seems of paramount importance 
to highlight here that benign lesions, or those associated 
to inflammation, can also be characterized by a loss of 
stromal AF, which grossly limits the diagnostic specifi-
city, especially in low-risk populations.
Mean SE and SP for this tool, were 72.4% and 63.79%, 
respectively. It is opinion of the authors that such values, 
at the moment, are unacceptable for a tool specifically 
dedicated to the diagnosis of oral mucosal malignant le-
sions. However, it should be stressed that there are ap-
parently no other non-invasive visual diagnostic tools 
significantly better than AF-based tools. 
It is somewhat surprising that values of SE range from 
20% to 100% and value of SP goes from 15.3% to 
100%. 
Level of EBM for the selected studies seem to be quite 
acceptable, being ≥ 2b for all the studies, except one (3b 
level) (24). It is worthy mentioning that the study with 
the highest EBM level (1b) showed high values both of 
SE and SP (100% and 74%, respectively) (33).
- Chemiluminescence (CL)
The ViziLite® (VL - Zila Pharmaceuticals, Phoenix, 
AZ) was the first FDA-approved (2002) adjunctive tech-
nology to conventional head and neck examination for 
improving visualization of early dysplastic or neoplas-
tic lesions. This system involves an oral rinse with a 1% 
acetic acid solution for 1 minute, to remove the glyco-
protein barrier and slightly desiccate the oral mucosa. A 
diffuse chemiluminescent blue/white light with an aver-
age wavelength of 490 to 510 nm is then activated and 
used to examine the oral tissues. Normal cells absorb 
the light and appear blue, whereas abnormal cells have 
a higher nuclear/cytoplasmic ratio and should reflect the 
light appearing whiter with brighter, sharper, more dis-
tinct margins (15,36,38).
Mean SE and SP resulted 86.72% and 38.37%, respec-
tively. All the analysed studies have an EBM level of 
2b, but there is a great inhomogeneity especially for SP, 
which ranges from 14.2% to 81.5%.  
- Toluidine Blue (TB)
Toluidine blue (TB), also known by its chemical name 
tolunium chloride (TC), is a cationic met achromatic 
dye that may selectively bind to free anionic groups 
such as sulfate, phosphate, and carboxyl ate radicals of 
large molecules. It has been used for decades as aid to 
the identification of mucosal abnormalities of the cervix 
as well as those in the oral cavity (8). 
TB stains deoxyribonucleic acid and/or may be retained 
in intracellular spaces of dysplastic epithelium, which 
clinically appears as royal blue areas. It is postulated 
that the increased amount of DNA and RNA in neoplas-
tic cells and the wider intercellular canals compared to 
normal epithelial cells are responsible for staining ma-
lignant cells (11).
Mean SE and SP were 72.5% and 61.4%, respectively. 
These values are poorly acceptable in oncologic diagno-
sis and they seem to be more realistic because standard 
deviations are lower than those calculated for the other 
diagnostic tools.  
- Chemiluminescence associated with Toluidine Blue 
(CLTB)
In order to reduce the high number of false positive 
cases obtained through VL, the manufacturer added TB 
(ViziLite Plus® - VLP) (12,22).
Data related to the use of this technique are very poor 
and discordant; mean SE and SP were 53.93% and 
66.44%, respectively, but standard deviations were ex-
cessively high.
- Rose Bengal (RB)
Rose Bengal (RB) is the 4,5,6,7-tetrachloro- 2’,4’,5’,7’-
tetraiodo-derivative of fluorescein. It has been widely 
used to diagnose various ocular surface disorders. It has 
been believed to stain desquamated ocular epithelial 
cells, dead or degenerated cells but not healthy epithelial 
cells. RB staining was even used to delineate the extent 
of corneal and conjunctival neoplasms. Therefore, such 
findings of RB enlightened us to carry out researches 
in detection of oral precancerous and malignant lesions 
(9,23).
Data on SE and SP related to this tool are scarce and 
resulting from studies of low OEBM level (3b). 
- Laser-induced fluorescence examination (LIFE)
This technique is based on AF of the tissue as well as 
DVFE. The instrumentation proposed by Mallia et al. is 
comprised of a diode laser (Stocker Yale, Canada, 404 
nm, 50 mW, CW) for excitation of tissue fluorophores 
(21). Light emission from the laser source is guided to 
the oral mucosa through a 3 µm long bifurcated fiber 
optic probe that has a central fiber to deliver the excita-
tion beam and 6 surrounding fibers (400 µm diameter 
each) to collect AF emissions. The red to green colour 
ratio is defined as the numerical color value (NCV).
Two studies regarding this tool have been selected for 
this review. SE and SP values are reported in 1 study 
only and they are high (SE: 100%-95%; SP: 96%-86%, 
according to the histopathological diagnosis), but the 
OEBM level is low (4). Data from further studies with a 
higher OEBM level are necessary.
- 5-aminolevulinic acid (ALA) induced protoporphyrin 
IX (PPIX) fluorescence
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Only one perspective study describing this technique 
was selected for this review (29).  Topical or systemic 
administration of 5-ALA results in a selective accumu-
lation of PPIX in neoplastic tissue, which is probably 
due to altered activity levels of the enzymes of the heme 
biosynthetic pathway within malignant transformed 
cells. In the protocol of Leuing et al., the patients per-
formed a 15-minute continuous rinsing of the oral cav-
ity using the 5-ALA solution. After an incubation pe-
riod of 1 to 2.5 hours (maximum contrast after 1.5h), 
fluorescence investigation was performed. In 13.8% of 
the patients, additional findings like dysplasia, carci-
noma in situ, OSCC were found through fluorescence 
in contrast to COE (27). An evaluation of the biopsy 
specimens resulted in a SP of 60% and a SE of 99% (29). 
ALA-induced fluorescence could represent a possible 
useful new diagnostic tool to detect early malignant le-
sions in the oral cavity. However, further studies seem 
to be necessary.
- Optical spectroscopy
Optical spectroscopy is a non-invasive diagnostic 
method that has been investigated in many forms in-
cluding fluorescence spectroscopy (FS), elastic or dif-
fuse scattering spectroscopy (ESS), and Raman spec-
troscopy (RS). Spectroscopic measurements can detect 
biochemical and architectural alterations in tissue that 
are related to the carcinogenesis. These alterations may 
include changes in the concentrations of native fluoro-
phores such as collagen, elastin, keratin, nicotinamide 
adenine dinucleotide (NADH), and flavin adenine di-
nucleotide (FAD); changes in hemoglobin concentra-
tion and oxygenation; increasing epithelial thickness; 
increasing nuclear size and nuclear/cytoplasmic ratio; 
change in vascularization (20,25,30,31).
These principles are employed within experimental 
methods; SE and SP values seem to be high, but there 
is need for more data. Only one study for each optical 
spectroscopy method was identified and they had a low 
OEBM level (4, 3b and 2b, respectively).
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